Monopar Therapeutics (NASDAQ:MNPR) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Monopar Therapeutics (NASDAQ:MNPR) issued its quarterly earnings data on Wednesday. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.03, Zacks reports.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock opened at $114.90 on Thursday. The stock has a 50-day moving average of $94.02 and a two-hundred day moving average of $70.99. Monopar Therapeutics has a one year low of $29.18 and a one year high of $124.82. The stock has a market cap of $769.83 million, a PE ratio of -60.47 and a beta of 1.47.

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds have recently modified their holdings of MNPR. Goldman Sachs Group Inc. acquired a new position in shares of Monopar Therapeutics in the first quarter valued at about $673,000. Jane Street Group LLC purchased a new stake in Monopar Therapeutics in the first quarter valued at approximately $377,000. Geode Capital Management LLC boosted its position in Monopar Therapeutics by 99.7% in the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after buying an additional 48,379 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the period. Finally, Rhumbline Advisers acquired a new position in Monopar Therapeutics in the 2nd quarter worth approximately $209,000. Institutional investors and hedge funds own 1.83% of the company’s stock.

Analysts Set New Price Targets

MNPR has been the topic of several analyst reports. UBS Group set a $125.00 target price on Monopar Therapeutics in a research note on Thursday, July 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. BTIG Research raised their price target on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a report on Wednesday. Wall Street Zen raised shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Three research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $117.42.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.